| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4858628
Max Phase: Preclinical
Molecular Formula: C15H17F3N2O3
Molecular Weight: 330.31
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CCCCOc1ccc(C2=NNC(=O)O[C@H]2C)cc1C(F)(F)F
Standard InChI: InChI=1S/C15H17F3N2O3/c1-3-4-7-22-12-6-5-10(8-11(12)15(16,17)18)13-9(2)23-14(21)20-19-13/h5-6,8-9H,3-4,7H2,1-2H3,(H,20,21)/t9-/m0/s1
Standard InChI Key: FOMOXZVSLJOJRE-VIFPVBQESA-N
Associated Targets(Human)
HeLa 62764 Activities
SK-MEL3 228 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
IGR-37 cell line 15 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 330.31 | Molecular Weight (Monoisotopic): 330.1191 | AlogP: 3.72 | #Rotatable Bonds: 5 |
| Polar Surface Area: 59.92 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
| #RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 10.52 | CX Basic pKa: | CX LogP: 3.89 | CX LogD: 3.89 |
| Aromatic Rings: 1 | Heavy Atoms: 23 | QED Weighted: 0.84 | Np Likeness Score: -0.61 |
References
| 1. Sabnis RW.. (2021) Novel Dihydrooxadiazinones as PDE3 Inhibitors for Treating Cancer., 12 (7.0): [PMID:34267873] [10.1021/acsmedchemlett.1c00317] |
Source
Source(1):